Drug Profile
Omalizumab biosimilar - BioXpress Therapeutics
Latest Information Update: 24 Nov 2021
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in Switzerland (SC, Injection)
- 16 Aug 2013 Preclinical trials in Allergic asthma in Switzerland (SC)